ATE110965T1 - Impfstoffe gegen hämophilus influenzae. - Google Patents

Impfstoffe gegen hämophilus influenzae.

Info

Publication number
ATE110965T1
ATE110965T1 AT90905112T AT90905112T ATE110965T1 AT E110965 T1 ATE110965 T1 AT E110965T1 AT 90905112 T AT90905112 T AT 90905112T AT 90905112 T AT90905112 T AT 90905112T AT E110965 T1 ATE110965 T1 AT E110965T1
Authority
AT
Austria
Prior art keywords
influencae
extracting
vaccines against
protein
influenzae
Prior art date
Application number
AT90905112T
Other languages
English (en)
Inventor
Bruce A Green
Gary W Zlotnick
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Application granted granted Critical
Publication of ATE110965T1 publication Critical patent/ATE110965T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT90905112T 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae. ATE110965T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09

Publications (1)

Publication Number Publication Date
ATE110965T1 true ATE110965T1 (de) 1994-09-15

Family

ID=23248627

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90905112T ATE110965T1 (de) 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae.
AT94100492T ATE195076T1 (de) 1989-03-09 1990-03-09 Verfahren zur isolierung von haemopnilus influenzae protein-e

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94100492T ATE195076T1 (de) 1989-03-09 1990-03-09 Verfahren zur isolierung von haemopnilus influenzae protein-e

Country Status (13)

Country Link
US (4) US5601831A (de)
EP (2) EP0462210B1 (de)
JP (1) JP2955014B2 (de)
KR (1) KR100188323B1 (de)
AT (2) ATE110965T1 (de)
AU (1) AU648251B2 (de)
CA (1) CA2047681C (de)
DE (2) DE69033600T2 (de)
DK (2) DK0462210T3 (de)
ES (2) ES2063965T3 (de)
FI (1) FI914241A7 (de)
NO (1) NO913518L (de)
WO (1) WO1990010458A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
EP0624376B1 (de) * 1993-05-13 2000-03-15 American Cyanamid Company Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA2218385A1 (en) * 1995-04-17 1996-10-24 Pierre Hauser Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
EP1030662B1 (de) * 1997-11-12 2006-08-02 F. Hoffmann-La Roche Ag Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
AU777738B2 (en) * 1999-06-25 2004-10-28 Wyeth Holdings Corporation Extraction of integral membrane proteins
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
WO2001013948A1 (en) * 1999-08-20 2001-03-01 The General Hospital Corporation Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
CN1549726A (zh) * 2000-07-31 2004-11-24 耶鲁大学 先天性免疫系统指导的疫苗
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
CA2446355A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
WO2002100891A2 (en) * 2001-06-12 2002-12-19 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003218162B2 (en) * 2002-03-15 2009-10-29 The Curators Of The University Of Missouri Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3311836A1 (de) 2005-04-08 2018-04-25 Wyeth LLC Multivalente pneumokokken- polysaccharidproteinkonjugatzusammensetzung
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
ES2557160T3 (es) * 2006-10-23 2016-01-22 Nestec S.A. Modulación del aroma y el sabor mediante biotransformación en productos lácteos
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2010204066B2 (en) * 2009-01-07 2015-03-19 Otsuka Pharmaceutical Co., Ltd. Method for detecting all Haemophilus influenzae
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) * 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
JPS62502262A (ja) * 1985-03-27 1987-09-03 ブロンコスタット・プロプライアタリー・リミテツド アジユバントを含有しないワクチン
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
NO913518D0 (no) 1991-09-06
EP0606921B1 (de) 2000-08-02
US5955580A (en) 1999-09-21
JP2955014B2 (ja) 1999-10-04
DK0606921T3 (da) 2000-09-04
ES2150450T3 (es) 2000-12-01
US5601831A (en) 1997-02-11
DE69012318D1 (de) 1994-10-13
EP0462210B1 (de) 1994-09-07
DE69012318T2 (de) 1995-03-09
FI914241A0 (fi) 1991-09-09
ES2063965T3 (es) 1995-01-16
CA2047681A1 (en) 1990-09-10
US6420134B1 (en) 2002-07-16
ATE195076T1 (de) 2000-08-15
DK0462210T3 (da) 1994-10-10
WO1990010458A1 (en) 1990-09-20
AU5332690A (en) 1990-10-09
FI914241A7 (fi) 1991-09-09
KR100188323B1 (ko) 1999-06-01
US5780601A (en) 1998-07-14
DE69033600D1 (de) 2000-09-07
DE69033600T2 (de) 2001-04-05
EP0606921A1 (de) 1994-07-20
JPH07508972A (ja) 1995-10-05
NO913518L (no) 1991-10-29
AU648251B2 (en) 1994-04-21
CA2047681C (en) 2000-02-01
EP0462210A1 (de) 1991-12-27

Similar Documents

Publication Publication Date Title
ATE110965T1 (de) Impfstoffe gegen hämophilus influenzae.
PT82610B (pt) Processo para a preparacao de tiazolidino-dionas hipoglicemicas
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
CA2005291A1 (en) Feline infectious peritonitis virus diagnostic tools
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
LV5765A4 (lv) (S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
CA2098253A1 (en) Method for producing ectoprotein of hepatitis c virus
WO1996019498A3 (en) T cell stimulating protein of pestivirus
ATE62235T1 (de) Verfahren zur herstellung von 6-amino-3-hydrazino-pyridazinderivaten.
AU3417589A (en) Peptides
JPS53127808A (en) Preparation of human albumin
SE8102267L (sv) Forfarande for framstellning av ej koagulerbart blod medelst proteolytiska enzymer och proteinkoncentrat framstellt derur
JPS54160709A (en) Oncostatic substance and its preparation
AU5581186A (en) Protein absorption enhancing agent
ATE87976T1 (de) Verfahren zur herstellung von waessrigen loesungen von polysacchariden.
ATE7267T1 (de) Impfstoff und verfahren zu seiner herstellung.
IL78343A0 (en) Newcastle's disease virus(ndv)vaccine and method for the application thereof
ATE93725T1 (de) Pharmazeutische praeparate, die eine waesserige loesung eines pyranoquinolins enthalten.
AU583464C (en) Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues.
IT8349430A0 (it) Metodo per la produzione di proteine antigeniche specifiche del virusdell'epatite umana a, loro utilizzazione per la produzione di preparazioni farmaceutiche e mezzi diagnostici
KR870003064A (ko) 아미디노 우레아 유도체의 제조방법
MX9709525A (es) Vacunas de virus sincicial respiratorio de acido nucleico.
DE3676429D1 (de) Natriumsalz von etodolsaeure und verfahren zur herstellung.
SG83694G (en) Synthetic peptide and process of using same for the detection of antibodies to HTLV-III, diagnosis of aids and pre-aids conditions and as a vaccine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time